<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564482</url>
  </required_header>
  <id_info>
    <org_study_id>PETNEC</org_study_id>
    <secondary_id>2020-003142-37</secondary_id>
    <nct_id>NCT04564482</nct_id>
  </id_info>
  <brief_title>PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer</brief_title>
  <acronym>PETNEC</acronym>
  <official_title>Programmed Death-ligand 1 Positron Emission Tomography Imaging During Neoadjuvant (Chemo)radiothErapy in Esophageal and Rectal Cancer (PETNEC): a Prospective Non-randomized Open-label Single-center Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Laengle, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Christian Doppler Laboratory Applied Metabolomics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this pilot study is to prospectively monitor programmed death-ligand 1&#xD;
      (PD-L1) expression dynamics in vivo, during neoadjuvant chemoradiotherapy (CRT) or&#xD;
      short-course preoperative radiotherapy (SCPRT) in rectal and esophageal cancer by a positron&#xD;
      emission tomography (PET) imaging approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intratumoral changes of PD-L1 expression during neoadjuvant CRT/SCPRT</measure>
    <time_frame>3 weeks</time_frame>
    <description>Intratumoral PD-L1 expression dynamics induced by neoadjuvant CRT/SCPRT will be assessed by 89Zr-atezolizumab PET imaging (day 0 and between day 10-14).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic therapy response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Radiographic therapy response will be determined by magnetic resonance imaging-assessed tumor regression grade (mrTRG) for rectal cancer and PET response criteria in solid tumors (PERCIST) for esophageal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological therapy response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pathological therapy response will be determined according to the latest American Joint Committee on Cancer/International Union Against Cancer-Tumor Node Metastasis (AJCC/UICC-TNM) staging and tumor regression grade (TRG).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rectal Cancer Stage</condition>
  <condition>Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemoradiotherapy (CRT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Short-course preoperative radiotherapy (SCPRT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemoradiotherapy (CROSS protocol)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CRT</intervention_name>
    <description>50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO</description>
    <arm_group_label>Neoadjuvant Chemoradiotherapy (CRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SCPRT</intervention_name>
    <description>25 Gy in 5 Gy fractions over 5 working days</description>
    <arm_group_label>Short-course preoperative radiotherapy (SCPRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CROSS Protocol</intervention_name>
    <description>41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W</description>
    <arm_group_label>Neoadjuvant Chemoradiotherapy (CROSS protocol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PD-L1 PET</intervention_name>
    <description>10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.</description>
    <arm_group_label>Neoadjuvant Chemoradiotherapy (CROSS protocol)</arm_group_label>
    <arm_group_label>Neoadjuvant Chemoradiotherapy (CRT)</arm_group_label>
    <arm_group_label>Short-course preoperative radiotherapy (SCPRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  All sexes&#xD;
&#xD;
          -  Histologically confirmed carcinoma of the rectum or oesophagus (squamous cell&#xD;
             carcinoma and adenocarcinoma, including oesophago-gastric junction cancers)&#xD;
&#xD;
          -  Medical need for a neoadjuvant CRT/SCPRT&#xD;
&#xD;
          -  Suitable to withstand the course of neoadjuvant CRT/SCPRT&#xD;
&#xD;
          -  Written informed consent form (ICF) for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease, which is considered incurable by local therapies (expect for&#xD;
             oligometastatic disease with a curative intend)&#xD;
&#xD;
          -  Previous surgery of the tumor other than biopsy&#xD;
&#xD;
          -  Pregnancy, breastfeeding or expectancy to conceive&#xD;
&#xD;
          -  Prior therapy with anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2 or any other agent&#xD;
             directed against co-inhibitory T cell receptors or has previously participated in&#xD;
             clinical studies with immunotherapy&#xD;
&#xD;
          -  Disagreement of participants with reproductive potential to use contraception&#xD;
             throughout the study period and for up to 180 days after the last dose of study&#xD;
             therapy&#xD;
&#xD;
          -  Hepatitis B or C&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Immunodeficiency&#xD;
&#xD;
          -  Allogeneic tissue or solid organ transplantation&#xD;
&#xD;
          -  Autoimmune disease that has required systemic therapy in the past 2 years with&#xD;
             modifying agents, steroids or immunosuppressive drugs&#xD;
&#xD;
          -  Active non-infectious pneumonitis&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Systemic steroids or any other form of immunosuppressive therapy within 7 days prior&#xD;
             to the first dose of study treatment&#xD;
&#xD;
          -  Diagnosed and/or treated additional malignancy within 5 years of randomization, with&#xD;
             the exception of curatively-treated basal cell or squamous cell carcinoma of the skin&#xD;
             and/or curatively-resected in situ cervical and/or breast cancers&#xD;
&#xD;
          -  Treatment with botanical preparations (i.e. herbal supplements or traditional Chinese&#xD;
             medicines) intended for general health support or to treat the disease under study&#xD;
             within 2 weeks prior to randomization/treatment&#xD;
&#xD;
          -  Participants with serious or uncontrolled medical disorders&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease (myocardial infarction,&#xD;
             uncontrolled angina, any history of clinically significant arrhythmias, QTc&#xD;
             prolongation in males &gt; 450 ms and &gt; 470 ms in females, participants with history of&#xD;
             myocarditis)&#xD;
&#xD;
          -  Allergies and adverse drug reaction (history of allergy or hypersensitivity to study&#xD;
             drug components, contraindications to any of the study drugs of the chemotherapy&#xD;
             regimen)&#xD;
&#xD;
          -  Other exclusion criteria: Prisoners or participants who are involuntarily&#xD;
             incarcerated, participants who are compulsorily detained for treatment of either a&#xD;
             psychiatric or physical (i.e. infectious disease) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Haug, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Johannes Laengle, MD, PhD</investigator_full_name>
    <investigator_title>Sub-Investigator</investigator_title>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Oesophageal Cancer</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Short-course preoperative radiotherapy</keyword>
  <keyword>PD-L1 PET</keyword>
  <keyword>89Zr-atezolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

